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Abstract
Background: Folic acid (FA) added to foods during fortification is 70-85% bioavailable compared to 50% of folate
occurring naturally in foods. Thus, if FA supplements also are taken during pregnancy, both mother and fetus can
be exposed to FA exceeding the Institute of Medicine’s recommended tolerable upper limit (TUL) of 1,000
micrograms per day (μg/d) for adult pregnant women. The primary objective is to estimate the proportion of
women taking folic acid (FA) doses exceeding the TUL before and during pregnancy, and to identify correlates of
high FA use.
Methods: During 2005-2008, pre-pregnancy and pregnancy-related data on dietary supplementation were
obtained by interviewing 539 pregnant women enrolled at two obstetrics-care facilities in Durham County, North
Carolina.
Results: Before pregnancy, 51% of women reported FA supplementation and 66% reported this supplementation
during pregnancy. Before pregnancy, 11.9% (95% CI = 9.2%-14.6%) of women reported supplementation with FA
doses above the TUL of 1,000 μg/day, and a similar proportion reported this intake prenatally. Before pregnancy,
Caucasian women were more likely to take FA doses above the TUL (OR = 2.99; 95% = 1.28-7.00), compared to
African American women, while women with chronic conditions were less likely to take FA doses above the TUL
(OR = 0.48; 95%CI = 0.21-0.97). Compared to African American women, Caucasian women were also more likely to
report FA intake in doses exceeding the TUL during pregnancy (OR = 5.09; 95%CI = 2.07-12.49).
Conclusions: Fifty-one percent of women reported some FA intake before and 66% during pregnancy,
respectively, and more than one in ten women took FA supplements in doses that exceeded the TUL. Caucasian
women were more likely to report high FA intake. A study is ongoing to identify possible genetic and non-
genotoxic effects of these high doses.
Background
Previous studies have demonstrated that daily folic acid
(FA) supplementation during preconception lowers the
risk of neural tube defects [1-4] and other adverse preg-
nancy outcomes such as low birth weight [5]. Because of
this beneficial effect with no apparent adverse health out-
comes in pregnancy, FA supplementation of approximately
400 micrograms per day (μg/d) from fortified foods, sup-
plements, or both, was recommended for all women at risk
of pregnancy [3,6]. To meet this recommendation, women
take over-the-counter multivitamin supplements contain-
ing approximately 400 μg/d of FA [7]. Since clinical trials
data showed that the full benefit of FA was conferred prior
to conception and the national unintended pregnancy rate
in the US is 49% [8], a more effective vehicle to reach
women was pursued. In 1996, the Food and Drug Admin-
istration (FDA) approved population-wide fortification of
milled grain at 140 μg FA/100 grams [9] to deliver an addi-
tional 100 μg/d of FA to the average adult diet [10].
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limit has been reported among women of child-bearing age
[11,12].
Folic acid added to foods during fortification is 70-85%
bioavailable compared to 50% of folate occurring naturally
in foods [6,13]. Thus, if FA supplements also are taken
during pregnancy, both mother and fetus can be exposed
to FA exceeding the Institute of Medicine’s [6] recom-
mended tolerable upper limit (TUL) of 1,000 μg/d for
adult pregnant women. While folate is essential for supply-
ing methyl groups for nucleotide synthesis and DNA repli-
cation, the effects of high FA doses are unknown. What is
known is that since fortification began, American sero-
surveillance data indicate that circulating folate concentra-
tions in serum and erythrocytes have increased 50-100%
in the general population [14,15]. While FA supplementa-
tion use before and during pregnancy has been monitored
in numerous populations [16-21], the extent of high FA
use in pregnant women is unknown. Herein, we contribute
to the monitoring effort by estimating the proportion of
pregnant women reporting intake of FA doses exceeding
the TUL, and determining whether socio-demographic
and lifestyle factors are associated with high use within the
Newborn Epigenetics STudy (NEST).
Methods
Study participants
Study participants were recruited as part of the ongoing
Newborn Epigenetics STudy (NEST), a prospective study
of women and their children. NEST was designed to iden-
tify early exposures associated with stable epigenetic altera-
tions in infants that may alter chronic disease susceptibility
later in life. Trained recruiter/interviewers identified eligi-
ble participants by reviewing prenatal care appointment
logs in Duke’s Division of Maternal and Fetal Medicine at
the beginning of each week, and eligible participants were
invited to participate. Women were eligible if they were
aged 18 years and older, pregnant and spoke English. To
ensure access to labor and birth outcomes data, we
excluded women who planned to receive obstetric care
outside the Duke Obstetrics or Durham Regional Hospi-
tals. The catchment area for Duke Maternal Fetal Medi-
cine prenatal care clinic largely includes three contiguous
counties in central North Carolina (NC); Durham, Orange
and Wake. Women who met eligibility criteria were either
consented and interviewed in-person, in consultation
rooms during the visit, or were given the questionnaire to
self-administer and mail back to the study office. If com-
pleted questionnaires were not received in the mail by the
subsequent visit, another questionnaire was administered
during a prenatal care visit. Interviewer-administered ques-
tionnaires took approximately 15 minutes to complete. At
the end of the interview, all women were asked to provide
contact information that included names, address and at
least three telephone numbers to facilitate future contact.
Because in utero exposure to cigarette smoke is associated
with poor birth outcomes and may predict high FA use
[17,22], we targeted smokers to the extent possible, identi-
fying them through medical records.
Gestational age at enrollment ranged from 19 to
42 weeks (mean = 38.1; sd = 2.5 weeks). By June 2008,
838 eligible women had been identified and 601 were
enrolled (response rate of 71.7%). Most enrollees (98.2%)
were successfully followed to delivery (n = 590). Children
from these pregnancies are being followed to collect
growth data once every two years. These analyses include
539 participants with complete questionnaire and medi-
cal records data. The study protocol was approved by the
Duke University Institutional Review Board.
Data Collection
Domains for which information pertaining to the year
before and the year during pregnancy was solicited
included the following; demographic characteristics,
health status, reproductive factors, lifestyle factors such
as tobacco and alcohol use, anthropometric measure-
ments before pregnancy and dietary supplementation.
Although not used in the current analyses, diet was
assessed using the 24-hour dietary recall (Nutritional
Data Systems for Research, University of Minnesota).
Medical records were also abstracted to obtain informa-
tion on maternal morbidity and use of over-the-counter
and prescribed medication. At delivery, we collected
data related to labor, umbilical cord blood and birth
outcomes, including birth weight.
Folic acid supplementation
To ascertain FA intake, participants were shown a list of
dietary supplements that included multivitamins, multi-
vitamins with additives such as herbs, FA/folacin, vita-
min B6 (pyridoxine), vitamin B12 (cobalamin), and
“other,” and asked for Yes-No responses to the ques-
tions “In the 12 months before pregnancy, did you take
[dietary supplement]?”. To obtain folic acid intake dur-
ing pregnancy, women were asked to respond to the
question “Since you found out you were pregnant, did
you take [dietary supplement]?” Supplement users were
asked the brand name, the frequency of intake and tri-
mester when intake started, if intake started during
pregnancy. Study participants were unaware of the study
hypothesis. The frequency and dose of FA intake before
and during pregnancy was converted into daily μg/day
FA intake using dosage information provided on the
packet. Where specific brands were not recalled, a con-
servative value of 400 μg was assigned.
Statistical analyses
Women were categorized as non-users (no supple-
mentation), users within recommended range (intake
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(intake >1,000 μg/d). A dose of ≤1,000 μg/d was assigned
to women reporting “over-the-counter daily multivitamin”
as these supplements provide ~400 μg/d of FA. Women
taking “additional FA” providing ~800 μg/d of FA, and
those reporting intake of “prenatal vitamins only” which
provide ~600-1,000 μg/d of FA, were also included in the
category of users within the recommended range. Doses
exceeding 1,000 μg/d were assigned to women who
reported intake of a combination of “prenatal vitamins”
including those prescribed (~600-1,000 μg/d) and “over-
the-counter multivitamins” (~400 μg/d) of FA, and/or
multivitamins with “additional FA” (~400 μg/d). Total FA
intake ranged from 0 to >1,600 μg/d.
FA supplementation before and during pregnancy was
examined in relation to factors previously identified to
predict any FA use including ethnicity [23], advanced
maternal age [24], socioeconomic indicators (education,
marital status and public or private health insurance)
[17,24] reproductive factors such as parity [17], use of
cigarettes [17] and alcoholic or caffeinated beverages. We
also evaluated FA supplementation in relation to factors
not previously described, including participants’ self-
reported health indicators, a history of chronic illness
(asthma, hypertension, depression, cardiovascular dis-
eases, allergies, migraines, epilepsy, anxiety, cancer, gesta-
tional diabetes) and the use and type of assisted
reproductive technology (ART) used in infertility treat-
ments since infertility is also associated with FA use [17].
We estimated the proportions and 95% confidence inter-
vals (95% CIs) of women reporting FA use exceeding the
TUL, and examined correlates of use that could be used to
target women for further study and possible intervention.
Unconditional logistic regression models were used to
estimate odds ratios (ORs) and 95% CIs for the association
between each correlate and FA supplementation. Non-
users were compared to users within recommended range
(≤1,000 μg/d), and users exceeding the TUL (>1,000 μg/d),
separately for use before and during pregnancy. Cigarette
smoking was included in all statistical models except when
we stratified by cigarette smoking. Independent effects
were evaluated by mutual adjustment in parsimonious
models. All statistical analyses were conducted in SAS
v9.03 (SAS Institute Inc., Cary, NC).
Results
Characteristics presented in Table 1s u g g e s tt h a ts t u d y
participants were similar to the general pregnant popu-
lation in the three-county region of NC with respect to
age, marital status and education of African Americans
and Whites [25]. However, study participants were
more likely to smoke or be exposed to environmental
Table 1 Characteristics of New Born Epigenetics STudy
(NEST) Study Participants
Maternal Characteristic (n = 539)
Number (%)
Maternal age at beginning of pregnancy
<25 years 166 (30.8)
25-34 years 261 (48.4)
35-39 91 (16.9)
40+ 20 (3.7)
Missing 1 (0.2)
Maternal ethnicity
African American 258 (47.9)
Caucasian 246 (45.6)
Asian/Native American/Latino 26 (4.8)
Missing 9 (1.7)
Maternal marital status
Never married 154 (28.6)
Married 241 (44.7)
Living with partner 99 (18.4)
Divorced/separated 44 (8.2)
Missing 1 (0.2)
Maternal education
Less than high school 63 (11.7)
High school graduate/GED 146 (27.1)
Some college 145 (27.1)
College graduate 98 (18.2)
Graduate education 86 (16.0)
Missing 1 (0.2)
Type of health insurance
Public (e.g., Medicaid, SCHIP) 250 (46.4)
Private 174 (32.3)
Missing 115 (21.3)
Parity
One 173 (32.1)
Two 113 (21.0)
Three or more 241 (44.7)
Missing 12 (2.2)
Cigarette smoking at interview
Non-smokers 425 (78.9)
Smoker during pregnancy 113 (21.0)
Missing 1 (0.1)
Exposure to secondhand smoke during index
pregnancy
Yes 158 (29.3)
No 375 (69.6)
Missing 6 (1.1)
Pre-pregnancy body size
<18 kg/m2 6 (1.1)
≥18 g/m2 - <25 kg/m2 164 (30.4)
≥25 kg/m2 - <30 kg/m2 96 (17.8)
≥30 kg/m2 206 (38.2)
Missing 66 (12.2)
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FA supplementation before and during pregnancy
Overall, 51% (95%CI = 47-55%) of women reported
some FA use before pregnancy. Recommended FA doses
(≤1,000 μg/d) taken either as a multivitamin or a single
dietary supplement were reported by 209/539 or 39%
(95%CI = 35%-43%), and intake of doses exceeding the
TUL for adults (>1,000 μg/d) was reported by 12% (95%
CI = 9%-15%) of women before pregnancy [Table 1].
During pregnancy, some FA use was reported by 66%
(95%CI = 62%-70%) of women. FA intake within recom-
mended doses of ≤1,000 μg/d was reported by 295/539
or 55% (95%CI = 51-59%), and intake of doses exceed-
ing the TUL for adults of >1,000 μg/d was reported by
11% (95%CI = 8%-14%) of women. Because we targeted
smokers, we also evaluated whether FA use exceeding
the TUL varied by smoking status. We found no statisti-
cally significant differences in FA use by smoking status
as 6% (95%CI = 2%-11%) of smokers and 13% (95%CI =
10%-17%) of non-smokers reported FA intake ≥1,000
μg/d before pregnancy (p-value = 0.11) (data not
shown). During pregnancy, the proportion of women
reporting FA use exceeding TUL for adults was also
similar in smokers 12% (95%CI = 6%-17%) and non-
smokers 11% (95%CI = 8%-14%) (p-value = 0.81).
Correlates of dietary folic acid supplementation
FA supplementation before pregnancy
Compared to non-users, FA intake exceeding 1,000 μg/d
before pregnancy was reported more frequently by
women who were aged >35 years (OR = 5.5, 95% CI =
2.3-13.2), married or living with partner (OR = 3.5, 95%
CI = 1.9-6.6), privately insured (OR = 4.7,95%CI =
2.5-8.9), Caucasian (OR = 3.6, 95%CI = 2.0-6.5), and
women with a college or higher education (OR = 8.5,95%
CI = 2.0-36.3). Smokers (OR = 0.4, 95%CI = 0.2-0.8),
those exposed to second hand smoke (OR = 0.4, 95%CI =
0.2-0.9) and those reporting any chronic disease (OR =
0.4, 95%CI = 0.2-0.8), were less likely to report FA intake
exceeding the TUL. Mutual adjustment of these factors
revealed some attenuation of these effects as FA intake
exceeding the TUL remained significantly more likely to
be reported by Caucasian women (adjusted OR = 3.0,
95% CI = 1.3-7.0), and less likely by women reporting at
least one chronic condition during pregnancy (adjusted
OR = 0.5, 95% CI = 0.2-1.0). The direction of the associa-
tion between high FA intake and advanced maternal age
(adjusted OR = 2.2, 95% CI = 0.8-6.4), being married or
living with a partner (adjusted OR = 1.9, 95% CI = 0.9-
4.0), and having a college or higher education (OR = 7.6,
95% CI = 0.9-65.2) were maintained in multivariate ana-
lyses, although the magnitude of associations was attenu-
ated [Table 2]. The direction and magnitude of these
associations was similar among FA users exceeding the
TUL and those whose intake was within recommended
doses, and among smokers.
FA supplementation during pregnancy
Table 2 also shows that FA use exceeding 1,000 μg/d dur-
ing pregnancy was associated with maternal age >35 years
(OR = 2.4, 95%CI = 1.0-5.7), Caucasian race/ethnicity (OR
= 6.4; 95%CI = 3.4-12.2), being married (OR = 2.2, 95%CI
= 1.2-4.0), having a college or higher education (OR = 2.7,
95%CI = 1.0-7.0), being privately insured (OR = 3.0, 95%
CI = 1.5-5.8), and having had three or more live births
(OR = 0.4, 95%CI = 0.2-0.8). After simultaneous adjust-
ment for each factor, being Caucasian (OR = 5.1, 95% =
2.1-12.5) remained associated with intake of FA doses
exceeding the TUL. Interestingly, being Caucasian was
also associated with FA use within recommended ranges
(OR = 4.7, 95% = 2.6-8.5). Similar patterns of association
emerged in smokers and in non-smokers.
Five percent of women reported FA supplementation
≥1,000 μg/d both before pregnancy and during preg-
nancy, and 75% were Caucasians with a college or
higher education.
Table 1 Characteristics of New Born Epigenetics STudy
(NEST) Study Participants (Continued)
Therapeutic interventions
Hormonal contraceptive us up to one year before
interview
135 (25.1)
Use of assisted reproductive technology for index
pregnancy
17 (3.2)
Co-morbid conditions at interview
None 341 (63.3)
Gestational diabetes 42 (7.8)
Type 1 or Type 2 diabetes 27 (5.0)
Asthma 88 (16.3)
*Other 39 (7.2)
**Any chronic disease 196 (36.4)
Folic acid intake before pregnancy
None 265 (49.2)
Up to 1,000 μg/day 209 (38.8)
More than 1,000 μg/day 64 (11.9)
Missing 1 (0.2)
Folic acid intake during pregnancy
None 182 (33.8)
Up to 1,000 μg/day 295 (54.7)
More than 1,000 μg/day 61 (11.3)
Missing 1 (0.2)
*Other includes hypertension, depression, heart diseases, allergies, migraine
headaches, epilepsy, anxiety, treated for cancer.
**Any chronic disease includes gestational diabetes, asthma, hypertension,
depression, diabetes mellitus, heart diseases, allergies, migraine headaches,
epilepsy, anxiety, treated for cancer.
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during pregnancy
FOLIC-ACID USE BEFORE PREGNANCY FOLIC-ACID USE DURING PREGNANCY
Characteristic None n
= 265
<1,000
μg/day
n = 209
≥ 1,000
μg/day
n=6 4
<1,000 μg/day
OR(95%CI)
≥ 1,000 μg/day
OR(95%CI)
None n
= 182
<1,000 μg/day
n = 295
≥ 1,000 μg/
day n = 62
<1,000 μg/day
OR(95%CI)
≥ 1,000 μg/day
OR(95%CI)
Maternal age at beginning of
pregnancy
<25 years 107 50 9 1.00 1.00 69 81 16 1.00 1.00
25-34 years 117 107 36 1.42 (0.83-2.43) 2.21 (0.87-5.59) 90 137 33 0.65 (0.37- 1.14) 0.82 (0.32-2.09)
35+ 41 51 19 1.31 (0.68-2.54) 2.20 (0.76-6.42) 22 77 12 1.60 (0.77-3.33) 1.49 (0.44-5.06)
Maternal ethnicity
African American 165 71 21 1.00 1.00 137 98 22 1.00 1.00
Caucasian 85 122 39 2.00 (1.18-3.38) 2.99 (1.28- 7.00) 35 175 36 4.70 (2.60-8.51) 5.09 (2.07-12.49)
Asian/Native American 12 12 2 1.04 (0.39-2.80) 0.87 (0.15- 5.00) 8 16 2 1.10 (0.40-3.01) 0.77 (0.13-4.52)
Maternal marital status
Married or live with partner 127 164 49 2.66 (1.59-4.45) 1.92 (0.86-4.33) 84 215 40 1.44 (0.87-2.41) 1.10 (0.46-2.69)
Not married or living with
partner
137 45 15 1.00 1.00 97 80 21 1.00 1.00
Maternal education
Less than high school 41 19 2 1.00 1.00 26 31 6 1.00 1.00
High school graduate/GED 97 39 10 1.12 (0.47-2.65) 3.40 (0.37-31.1) 78 61 7 0.85 (0.38-1.93) 0.62 (0.13-3.01)
College graduate/Graduate
school Some college
126 151 52 1.70 (0.74-3.90) 7.60 (0.89-65.2) 77 203 48 1.69 (0.74-3.86) 2.37 (0.53-10.6)
Second hand smoke
Yes 98 47 13 0.63 (0.36-1.12) 1.42 (0.57-3.50) 73 69 16 0.48 (0.27-0.84) 0.54 (0.21-1.38)
No 165 159 50 1.00 1.00 107 222 45 1.00
Parity
One 80 71 22 1.00 1.00 45 103 25 1.00 1.00
Two 51 46 16 1.02 (0.55-1.90) 1.63 (0.65-4.09) 36 63 14 0.90 (0.46-1.78) 0.73 (0.26-2.04)
Three or more 126 89 25 1.07 (0.62-1.85) 1.74 (0.69-4.04) 94 126 20 1.12 (0.61-2.04) 0.65 (0.26-1.62)
Pre-pregnancy body mass
index
<25 kg/m
2 76 67 27 1.00 1.00 46 101 24 1.00 1.00
≥25 kg/m
2 155 114 32 1.07 (0.67-1.71) 0.79 (0.39-1.59) 108 164 29 0.83 (0.50-1.39) 0.46 (0.20-1.05)
Co-morbid conditions
Any chronic disease 105 77 13 0.83 (0.52-1.31) 0.45 (0.21-0.97) 70 101 24 0.92 (0.56-1.50) 0.95 (0.43-2.12)
None 159 131 51 1.00 1.00 110 194 37 1.00 1.00
Cigarette smoking during
pregnancy
Yes 69 36 7 0.82 (0.43-1.56) 0.40 (0.12-1.28) 36 64 13 2.37 (1.21-4.65) 1.39 (0.46-4.19)
No 195 173 57 1.00 1.00 145 231 48 1.00 1.00
*Odds ratios are mutually adjusted, referents are women reporting no supplement use.
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8Discussion
Our key findings were that overall, 51% of women
reported some FA intake before pregnancy and 66%
reported the same during pregnancy. In addition, more
than 10% of women reported daily FA supplementation
exceeding the TUL before or during pregnancy. Notably,
5% of the women reported taking FA exceeding the
TUL, both before and during pregnancy. FA intake
exceeding TUL was most frequently reported by Cauca-
sian women, and least frequently by those reporting at
least one morbid condition. Borderline associations were
also found with advanced maternal age and having a
college or higher education. Recently, data from the
National Health and Nutrition Examination Survey esti-
mated that in women of childbearing age, ~1% of
women are exposed to FA doses exceeding 1,000 μg/d
from fortified food alone, and 26% report FA intake in
doses exceeding the recommended 400 μg/d [23].
Median folate intake among women of child-bearing
age in the US is 450 μg/d (range 154-2,800ug/d) and
approximately 75% is contributed by FA [10,23].
Because synthetic folate, or FA, is 70-85% bioavailable
compared to 50% of folate occurring naturally in food
[6], these findings suggest a sizable subpopulation of
mothers and fetuses may be exposed to what some
describe as supraphysiological folate levels [26]. To date,
the adverse health effects of such exposure are unknown
in humans. However, circulating folate levels have
approximately doubled in the last decade [14,15]. Some
large observational and randomized clinical trial data
[27,28], but not all [29], suggest an increased risk of
twin pregnancies in women with high circulating serum
folate levels during pregnancy, independent of age and
fertility. High FA intake early in pregnancy also has
been linked to an increase in the frequency of the
methylenetetrahydrofolate reductase (MTHFR) 677T-
allele in the fetus [30,31]. Carrying this genetic variant
has been associated with chronic conditions including
depression, schizophrenia, bipolar disorder, asthma, and
wheezing later in life [32-35]. Conversely, peri-concep-
tional FA intake >400 μg/d was recently associated with
improvements in cytosine-guanine (CpG) methylation at
the insulin-like growth factor (IGF2) differentially methy-
lated region (DMR) that regulates IGF2 imprinting in
children [36]. Loss of imprinting at this IGF2 DMR has
been associated with a higher risk of overgrowth disor-
ders in childhood [37] and colon cancer in adulthood
[38]. Our findings would suggest that a sizable propor-
tion of pregnant women and their fetuses are exposed
to FA exceeding the TUL. Because the original TUL was
based on the potential for excessive folate to mask vita-
min B12 deficiency (rare in pregnant women), and there
are potential epigenetic benefits of FA supplementation,
it is prudent to continue to monitor dosages of FA
exposure in the population, and study its possible effects
towards the goal of establishing limits based on the gen-
otoxic and non-genotoxic effects.
T h ee s t i m a t eo f6 6 %F Au s ed u r i n gp r e g n a n c yi no u r
study is consistent with previous reports among preg-
nant women in the US [39,40] and other developed
countries [29]. While the use of FA before pregnancy
by 51% of women in the current study is higher than
reports from previous studies of non-pregnant women
in the US, which ranged from 27% in Arkansas to 44%
in Rhode Island [39-44], it is similar to the 53%
recently reported in an American six-site, hospital-
based study [16]. The significance of the inverse asso-
ciation between morbidity and FA exceeding the TUL
is unclear although it may reflect increased counseling
of FA users since such conditions require frequent
contact with health care providers. Associations
between Caucasian race/ethnicity and high FA intake
are consistent with previous reports where any FA
supplementation was evaluated [39,45], and may reflect
increased knowledge of B vitamin pharmacokinetics
w h e r ee x c e s si n t a k em a yn o tb ev i e w e da sh a r m f u l .
More probable is that Caucasian race/ethnicity and
perhaps advanced maternal age and higher education
represent greater wherewithal to access supplemental
FA, suggesting a need for population-wide re-educa-
tion on currently recommended FA use.
While the design is hospital-based, the distribution of
demographic characteristics in this population is similar
to that of the three-county region from which study par-
ticipants largely arose [25,46] and are consistent with
those reported by previous studies evaluating FA intake
in the US and elsewhere [18,44,47,48]. A limitation of
o u rf i n d i n g si st h a tw ew e r eu n a b l et oe v a l u a t et h e
potential effect of unplanned pregnancy in the associa-
tion between potential correlates and FA supplementa-
tion. It is possible that FA intake exceeding TUL, during
the prenatal period may be influenced by a desire to
compensate for non-FA intake during peri-conception.
The interpretation of these findings is also limited by
our inability to prospectively monitor dosages of FA
before and during pregnancy. Therefore, confirmation of
these findings in larger studies will require active fol-
low-up and validation of self-reports with serial mea-
surement of maternal erythrocyte folate concentrations
and dietary assessments. Meanwhile, prudence dictates
that recommended FA doses are used by all women
planning a pregnancy.
Conclusions
In summary, while the FDA goal of consuming at least
400 μg/d of FA pre-conceptionally has been achieved by
50% of women of childbearing age, more than one-tenth
of pregnant women consume daily doses that exceed the
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exceeding the TUL was associated with Caucasian race/
ethnicity, advanced maternal age and a college or higher
education. This study is part of a larger effort to charac-
terize the role of early exposures on genetic and epige-
netic perturbations in humans.
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